Sunesis Pharmaceuticals


Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for vosaroxin as a treatment …

Company Update (NASDAQ:SNSS): Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that it has initiated a Compassionate Use Program for vosaroxin.

Sunesis’ Shares Will Perform Well In 2015, Says Roth Capital

Roth Capital analyst Joseph Pantginis upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from Hold to Buy, and raised his price target to $4.30 (from $2.

Cantor Upgrades Sunesis Pharmaceuticals To Buy Ahead Of FDA Meeting In Early 2015

In a research report released earlier today, Cantor analyst Mara Goldstein upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from Hold to Buy and doubled her …

Roth Capital Reiterates Neutral On Sunesis Following Data From Phase I/II AML/MDS Study

Roth Capital analyst Joseph Pantginis reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2.30 price target, as the company presented data from its ongoing …

Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH

In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.

Cantor Fitzgerald Maintains Hold On Sunesis Pharma, Sees 6% Downside For The Stock

In a research note published this morning, Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2 …

Roth Capital Maintains Neutral On Sunesis, Sees 24% Downside

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a …

Sunesis: Vosaroxin Approval In The US And EU Is Unlikely, Says Wedbush

In a research report issued October 6 to investors, Wedbush analyst David Nierengarten reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) and significantly reduced his …

Sunesis: Investors Should Now Remain On The Sidelines, Says Roth Capital

In a research report issued today, Roth Capital analyst Joseph Pantginis downgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a Buy to a Neutral rating and lowered …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts